Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultra-rare genetic diseases, announced that CFO and Executive VP Howard Horn will participate in a fireside chat at Bank of America's 2025 Healthcare Conference. The event is scheduled for Tuesday, May 13, 2025, at 8:00 a.m. PT. Investors and interested parties can access both the live and archived webcast of the panel through Ultragenyx's investor relations website.

News Market Reaction – RARE

+7.66%

+7.66% Session move

In the trading session that priced this news, RARE gained 7.66%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America’s 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

FAQ

When is Ultragenyx (RARE) presenting at Bank of America's 2025 Healthcare Conference?

Ultragenyx will present at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.

Who will represent Ultragenyx (RARE) at the Bank of America Healthcare Conference 2025?

Howard Horn, Ultragenyx's Chief Financial Officer and Executive Vice President, will represent the company at the conference.

How can investors access Ultragenyx's (RARE) presentation at the Bank of America Healthcare Conference?

Investors can access both the live and archived webcast of the presentation through Ultragenyx's investor relations website at https://ir.ultragenyx.com/events-presentations.

What type of company is Ultragenyx Pharmaceutical (RARE)?

Ultragenyx is a biopharmaceutical company that focuses on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases.